Market Place
Sourcing Support
Enveric Biosciences Reports Q3 2024 Financial & Corporate Results
14 Nov 2024 //
BUSINESSWIRE
Enveric Biosciences Signs Out-Licensing Deal for EB-002
12 Nov 2024 //
BUSINESSWIRE
Enveric Biosciences Announces Broad Range of Patent Issuances
04 Nov 2024 //
BUSINESSWIRE
Enveric Announces Positive Safety Data for Lead Product, EB-003
15 Oct 2024 //
BUSINESSWIRE
Enveric Presents EB-003 Data At Pharmacology Workshop
26 Sep 2024 //
BUSINESSWIRE
Enveric Presents Data On EB-003 At Neuropsychiatric Summit
25 Sep 2024 //
BUSINESSWIRE
Enveric Biosciences to Present at H.C. Wainwright Annual Investment Conference
04 Sep 2024 //
BUSINESSWIRE
Aries And Enveric Announce US Patent For Radiation Dermatitis Treatment
13 Aug 2024 //
BUSINESSWIRE
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
12 Aug 2024 //
BUSINESSWIRE
Enveric Reports Preclinical Results Supporting Oral EB-003
25 Jul 2024 //
BUSINESSWIRE
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
15 Jul 2024 //
BUSINESSWIRE
Enveric Biosciences Announces Patent Granted for Drug Candidate
10 Jul 2024 //
BUSINESSWIRE
Enveric elevates EB-003 as lead development candidate with strategic update.
25 Jun 2024 //
BUSINESSWIRE
Enveric Biosciences to Participate in BIO International Convention 2024
30 May 2024 //
BUSINESSWIRE
Enveric Biosciences to out-license psilocin prodrug to MindBio
15 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
15 May 2024 //
BUSINESSWIRE
Enveric Biosciences: Non-Binding Term Sheet for Cancer Treatment
08 May 2024 //
BUSINESSWIRE
Enveric Biosciences Reports Financial Results and Provides Corporate Update
26 Mar 2024 //
BUSINESSWIRE
Enveric Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing
19 Mar 2024 //
BUSINESSWIRE
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets
12 Mar 2024 //
BUSINESSWIRE
Enveric Biosciences Signs Non-Binding Term Sheets
29 Feb 2024 //
BUSINESSWIRE
Enveric Agrees to Sell Cancer-Targeting Cannabinoid Intellectual Property
23 Feb 2024 //
BUSINESSWIRE
Enveric Biosciences Unveils Library of Preclinical Compounds
21 Feb 2024 //
BUSINESSWIRE
Enveric Updates Data Underpinning Selection of EB-003
03 Jan 2024 //
BUSINESSWIRE
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
28 Dec 2023 //
BUSINESSWIRE
Enveric Biosciences Reports Year End Progress for EB-373
27 Dec 2023 //
BUSINESSWIRE
Enveric to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
20 Dec 2023 //
BUSINESSWIRE
Enveric Biosciences Selects Development Candidates from EVM301 Series
05 Dec 2023 //
BUSINESSWIRE
Enveric Receives Notice of Allowance for Glycosylated Psilocybin Derivatives
29 Nov 2023 //
BUSINESSWIRE
Enveric Announces Manuscript Describing the Development of EB-373
27 Nov 2023 //
BUSINESSWIRE
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
13 Nov 2023 //
BUSINESSWIRE
Enveric Biosciences Receives Notice of Allowance from USPTO
31 Oct 2023 //
BUSINESSWIRE
Enveric Biosciences to Present at the Centurion One 5th Global Summit
20 Oct 2023 //
BUSINESSWIRE
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies
18 Oct 2023 //
BUSINESSWIRE
Enveric Biosciences Announces Two Poster Presentations
11 Oct 2023 //
BUSINESSWIRE
Enveric Biosciences Announces its Psybrary™ Portfolio
03 Oct 2023 //
BUSINESSWIRE
Enveric Announces Publication of Paper Describing a Novel Bioproduction Platform
27 Sep 2023 //
BUSINESSWIRE
Enveric Biosciences Expands IP Portfolio with New U.S. Patent
20 Sep 2023 //
BUSINESSWIRE
Enveric Biosciences to Present Poster Highlighting EVM301 Series
18 Sep 2023 //
BUSINESSWIRE
Enveric Files Provisional Patent Application for AI-based Computational Methods
11 Sep 2023 //
BUSINESSWIRE
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid
05 Sep 2023 //
BUSINESSWIRE
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global Conference
30 Aug 2023 //
BUSINESSWIRE
Enveric Strengthens IP with New U.S. Patent for Tryptamine-derived Prodrugs
28 Aug 2023 //
BUSINESSWIRE
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material
21 Aug 2023 //
BUSINESSWIRE
Enveric Biosciences Finalizes Manufacture of EB-373 for Preclinical Program
21 Aug 2023 //
CONTRACT PHARMA
Enveric Biosciences Reports Positive Results from EB-373
24 Jul 2023 //
BUSINESSWIRE
Enveric Reports Results Demonstrating Oral Bioavailability for EB-373
17 Jul 2023 //
BUSINESSWIRE
Enveric Bio Announces Development of Phase 1-Ready Formulation for EB-373
26 Jun 2023 //
BUSINESSWIRE
Enveric to Present at H.C. Wainwright 4th Annual Neuropsychiatry Conference
12 Jun 2023 //
BUSINESSWIRE
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301
05 Jun 2023 //
BUSINESSWIRE
Enveric Receives Notice of Allowance From USPTO for C4-Carboxylic Acid
24 May 2023 //
BUSINESSWIRE
Enveric Announces Manuscript Detailing the Development of Psilocin Prodrugs
22 May 2023 //
BUSINESSWIRE
Enveric Biosciences to receive US patent for novel prodrug of psilocin
19 May 2023 //
PHARMABIZ
Enveric Bio to Participate in 2023 BIO International Convention in Boston
19 May 2023 //
BUSINESSWIRE
Enveric Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
18 May 2023 //
BUSINESSWIRE
Enveric Biosciences Reports 1Q 2023 FYR Results and Operational Highlights
15 May 2023 //
BUSINESSWIRE
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
10 Apr 2023 //
BUSINESSWIRE
Enveric Reports Fourth Quarter and Year-End 2022 Financial Results
03 Apr 2023 //
BUSINESSWIRE
Enveric Biosciences opens Australian subsidiary to work on anxiety disorder
24 Mar 2023 //
BIOSPECTRUM ASIA
Enveric Selects Avance Clinical, in Preparation for Phase 1 Study of EB-373
23 Mar 2023 //
BUSINESSWIRE
